Skip to main content
SpringerLink
Log in

The effect of different treatment modalities on oxidative stress in COPD

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Oxidant/antioxidant interactions are known to be important processes in the pathogenesis of chronic obstructive pulmonary disease (COPD). We aimed to evaluate the effects of corticosteroids (CS), and Nacetylcysteine (NAC) on plasma oxidant/antioxidant levels in patients with COPD.

Methods

This study utilised a single-blind, randomised, placebo-controlled, parallel-group methodology. We enrolled 58 patients with stable COPD and 30 healthy controls with similar demographic profiles. The patients with COPD were randomly divided into three treatment groups. Group 1 received basal treatment (regular ipratropium bromide and beta-2 agonist as needed), placebo CS and placebo NAC. In addition to basal treatment, group 2 received oral CS (methylprednisolone 40 mg/day) and placebo NAC. Group 3 received basal treatment plus NAC (600 mg/day) and placebo CS. Each group received treatment for 15 days. We measured plasma malondialdehyde (MDA) and superoxide dismutase (SOD) at the start and the end of study.

Results

Post-treatment plasma MDA levels were significantly lowered only in group 2 (P=0.004). No significant differences were found with respect to erythrocyte SOD levels.

Conclusion

This study demonstrates that oral CS, by aiding the oxidant/antioxidant system, may offer a new therapeutic option in COPD treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2006. Global Initiative for Chronic Obstructive Lung Disease web site. Available at: www.goldcopd.com. Accessed April 2008.

  2. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;156:341–357.

    PubMed  CAS  Google Scholar 

  3. Hanta I, Kocabas A, Canacankatan N, Kuleci S, Seydaoglu G. Oxidant-antioxidant balance in patients with COPD. Lung. 2006;184:51–55.

    Article  PubMed  CAS  Google Scholar 

  4. Kurys E, Kurys P, Kuzniar A. Analysis of antioxidant enzyme activity and magnesium level in chronic obstructive pulmonary disease. Ann Univ Mariae Curie Sklodowska. 2001;56:261–266.

    CAS  Google Scholar 

  5. Kinnula V, Crapo J. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med. 2003;167:1600–1619.

    Article  PubMed  Google Scholar 

  6. Yildiz L, Kayaoglu N, Aksoy H. The changes of superoxide dismutase, catalase and glutathione peroxidase activities in erythrocytes of active and passive smokers. Clin Chem Lab Med. 2002;40:612–615.

    Article  PubMed  CAS  Google Scholar 

  7. Daga M, Chhabra R, Sharma B. Effects of exogenous vitamin E supplementation on the levels of oxidants and antioxidants in chronic obstructive pulmonary disease. J Biosci. 2003;28:7–11.

    Article  PubMed  CAS  Google Scholar 

  8. Kocyigit A, Erel O, Gur S. Effects of tobacco smoking on plasma selenium, zinc, copper and iron concentrations and related antioxidative enzyme activities. Clin Biochem. 2001;34:629–633.

    Article  PubMed  CAS  Google Scholar 

  9. Postma DS, Kerstjens HA. Are inhaled corticosteroids effective in chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 1999;160:S66–S71.

    PubMed  CAS  Google Scholar 

  10. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1635–1639.

    Google Scholar 

  11. De Raeve HR, Thunnissen FB, Kaneko FT, et al. Decreased Cu, Zn-SOD activity in asthmatic airway epithelium: correction by inhaled corticosteroid in vivo. Am J Physiol. 1997;272:148–154.

    Google Scholar 

  12. Fenech AG, Ellul-Micallef R. Selenium glutathione peroxidase and superoxide dismutase in maltese asthmatic patients: effect of glucocorticoid administration. Pulm Pharmacol Ther. 1998;11:301–308.

    Article  PubMed  CAS  Google Scholar 

  13. Bridgeman MM, Marsden M, Selby C, Morrison D, MacNee W. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax. 1994;49:670–675.

    Article  PubMed  CAS  Google Scholar 

  14. De Benedetto F, Aceto A, Dragani B, et al. Long-term oral N-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther. 2005;18:41–47.

    Article  PubMed  CAS  Google Scholar 

  15. Kasielski M, Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med. 2001;95:448–456.

    Article  PubMed  CAS  Google Scholar 

  16. Siafakas NM, Vermeire P, Piride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). ERS consensus statement. Eur Respir J. 1995;8:1398–1420.

    Article  PubMed  CAS  Google Scholar 

  17. McCord JM, Fridovich I. Superoxide dismutase an enzymatic function for erythrocuprein (hemocuprein). J Biol Chem. 1969;244:6049–6055.

    PubMed  CAS  Google Scholar 

  18. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358.

    Article  PubMed  CAS  Google Scholar 

  19. Montuschi P, Kharitonov SA, Barnes PJ. Exhaled carbon monoxide and nitric oxide in COPD. Chest. 2001;120:496–501.

    Article  PubMed  CAS  Google Scholar 

  20. Paredi P, Kharitonov SA, Leak D, Ward S, Cramer D, Barnes PJ. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:369–373.

    PubMed  CAS  Google Scholar 

  21. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med. 2000;162:1175–1177.

    PubMed  CAS  Google Scholar 

  22. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax. 2003;58:294–298.

    Article  PubMed  CAS  Google Scholar 

  23. MacNee W. Oxidants/antioxidants and COPD. Chest. 2000;117:S303–S317.

    Article  Google Scholar 

  24. Van Beurden WJC, Harff GA, Dekhuijzen PNR, van der Poel-Smet SM, Smeenk FWJM. Effects of inhaled corticosteroids with different lung deposition on exhaled hydrogen peroxide in stable COPD patients. Respiration. 2003;70:242–248.

    Article  PubMed  CAS  Google Scholar 

  25. Verhoeven GT, Wijkhuijs AJM, Hooijkaas H, Hoogsteden HC, Sluiter W. Effect of an inhaled glucocorticoid on reactive oxygen species production by bronchoalveolar lavage cells from smoking COPD patients. Mediators Inflamm. 2000;9:109–113.

    Article  PubMed  CAS  Google Scholar 

  26. Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharm. 2006;533:222–239.

    Article  CAS  Google Scholar 

  27. Sadowska AM, Klebe B, Germonpre P, De Backer WA. Glucocorticosteroids as antioxidants in treatment of asthma and COPD. New application for an old medication? Steroids. 2007;72:1–6.

    Article  PubMed  CAS  Google Scholar 

  28. Pereira B, Fernando L, Costa Rosa BP, Safi DA, Bechara EJH, Curi R. Hormonal regulation of superoxide dismutase, catalase and glutathione peroxidase activities in rat macrophages. Biochem Pharmacol. 1995;50:2093–2098.

    Article  PubMed  CAS  Google Scholar 

  29. Sadowska AM, Manuel-y-Keenoy B, De Backer WA. Antioxidant and anti inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effect: a review. Pulm Pharmacol Ther. 2007;20:9–22.

    Article  PubMed  CAS  Google Scholar 

  30. Sadowska AM, van Overveld FJ, Gorecka D, et al. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir Med. 2005;99:241–249.

    Article  PubMed  CAS  Google Scholar 

  31. Van Overveld FJ, Demkow U, Gorecka D, De Backer WA, Zielinski J. New developments in the treatments of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. J Physiol Pharmacol. 2005;56:135–142.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, Department of Chest Diseases, Cukurova University, Adana, Turkey

    Sedat Kuleci, Ismail Hanta & Ali Kocabas

  2. School of Medicine, Department of Biochemistry, Cukurova University, Adana, Turkey

    Necmiye Canacankatan

  3. School of Medicine, Department of Chest Diseases, Cukurova University, 01330, Balcali, Adana, Turkey

    Ismail Hanta

Authors
  1. Sedat Kuleci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ismail Hanta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Kocabas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Necmiye Canacankatan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ismail Hanta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuleci, S., Hanta, I., Kocabas, A. et al. The effect of different treatment modalities on oxidative stress in COPD. Adv Therapy 25, 710–717 (2008). https://doi.org/10.1007/s12325-008-0064-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-008-0064-4

Keywords

Search

Navigation